COVID-19 Clinical Trial Launches at University of Minnesota. March 17, 2020.
This trial is testing hydroxychloroquine, an FDA-approved medicine for the prevention and treatment of malaria, available since the 1950s and known as Plaquenil. Recent work shows that hydroxychloroquine is active in a laboratory setting against the novel SAS-CoV2 virus, and the trial is designed to see if it translates into benefits for people.FIFTEEN HUNDRED people. That ought to provide some statistically valid results.The trial seeks to enroll up to 1,500 people who have had household contact or those who are healthcare workers that have been exposed to someone with known COVID-19 disease within the past three days and who presently are not ill. The trial is national in scope.
In order to determine if taking the medicine hydroxychloroquine can prevent a person with exposure to the coronavirus from becoming ill or in reducing the severity of illness, the trial will provide hydroxychloroquine to half the study participants, while the other half will receive a vitamin.
To be eligible, one must live with someone who has diagnosed coronavirus COVID-19 or be a healthcare worker with a high-risk exposure within the past three days. The research study medicine will be delivered to their home overnight. If you think you may be eligible to participate in the trial, please email covid19@umn.edu for further instructions.
The trial is being limited to only high-risk exposures, so that the trial may be completed as quickly as possible with the fewest number of volunteers. At this time, people who may have been exposed to coronavirus in the community are currently not eligible to participate.
This is a first clinical trial to determine if this medicine is effective in preventing COVID-19 disease in humans. The trial is led by David Boulware, MD, MPH, a professor of Medicine in the Division of Infectious Diseases, with a collaborative team from throughout the University including infectious disease faculty physicians, biostatisticians, pharmacologists and students. The U of M is funding the trial.
“If effective, this may become a worldwide standard of care for helping prevent disease in other healthcare workers and people exposed,” Boulware said. “Hydroxychloroquine is an off-patent, generic medicine that is inexpensive. A five-day treatment course would cost approximately $12.”
Here is the thing.
Someone, or some outfit, wants to be the hero.
They CAN NOT stop the use of these meds.
If this study does comes out the way think it will. They will be hero’s even if they were never the first to do it.
So its now a race to see who is going to be the hero.
Fantastic
This is basically a test of Hydroxychloroquine’s use as a PROPHYLAXIS to prevent the disease.
Corona Test bump, in the unlikely event I need it.
Statistical significance depends partly on the number tested, and partly on the power of the treatment. If these treatments are as effective as they seem; an even smaller sample would tell the story. So, yes, this study should produce useful information.
COVID-19 Clinical Trial Launches at University of Minnesota. how long will it last?
this is what we need-something the fda types will approve of-I’d be praying I received the hydroxychloroquine